U.S. Drugmaker Alexion Pharma to acquire Synageva BioPharma for $8.4 billion
Wednesday, May 06, 2015
Drugmaker Alexion Pharmaceuticals Inc said it would buy Synageva BioPharma Corp for $8.4 billion to gain access to its experimental early-stage treatment for a rare metabolic disease.
Alexion's cash-and-stock offer values Synageva at $225.92 per share, representing a premium of 135.7 percent to the stock's close on Tuesday.
The deal is expected to add to Alexion's 2018 profit, while allowing $150 million in cost savings in 2017, the companies said in a statement on Wednesday.
uk.reuters.com
